



LUND UNIVERSITY

Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study.

Merritt, Melissa A; Riboli, Elio; Murphy, Neil; Kadi, Mai; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Dossus, Laure; Dartois, Laureen; Clavel-Chapelon, Françoise; Fortner, Renée T; Katzke, Verena A; Boeing, Heiner; Trichopoulou, Antonia; Lagiou, Pagona; Trichopoulos, Dimitrios; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Sacerdote, Carlotta; Panico, Salvatore; Bueno-de-Mesquita, H Bas; Peeters, Petra H; Lund, Eiliv; Nakamura, Aurelie; Weiderpass, Elisabete; Quirós, J Ramón; Agudo, Antonio; Molina-Montes, Esther; Larrañaga, Nerea; Dorronsoro, Miren; Cirera, Lluís; Barricarte, Aurelio; Olsson, Åsa; Butt, Salma; Idahl, Annika; Lundin, Eva; Wareham, Nicholas J; Key, Timothy J; Brennan, Paul; Ferrari, Pietro; Wark, Petra A; Norat, Teresa; Cross, Amanda J; Gunter, Marc J

Published in:
BMC Medicine

DOI:
[10.1186/s12916-015-0484-3](https://doi.org/10.1186/s12916-015-0484-3)

2015

[Link to publication](#)

Citation for published version (APA):

Merritt, M. A., Riboli, E., Murphy, N., Kadi, M., Tjønneland, A., Olsen, A., Overvad, K., Dossus, L., Dartois, L., Clavel-Chapelon, F., Fortner, R. T., Katzke, V. A., Boeing, H., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Sieri, S., Tumino, R., ... Gunter, M. J. (2015). Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study. *BMC Medicine*, 13, Article 252. <https://doi.org/10.1186/s12916-015-0484-3>

Total number of authors:
45

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

RESEARCH ARTICLE

Open Access



Reproductive factors and risk of mortality in the European Prospective Investigation into Cancer and Nutrition; a cohort study

Melissa A. Merritt^{1*}, Elio Riboli¹, Neil Murphy¹, Mai Kadi¹, Anne Tjønneland², Anja Olsen², Kim Overvad³, Laure Dossus^{4,5,6}, Laureen Dartois^{4,5,6}, Françoise Clavel-Chapelon^{4,5,6}, Renée T. Fortner⁷, Verena A. Katzke⁷, Heiner Boeing⁸, Antonia Trichopoulou^{9,10,11}, Pagona Lagiou^{10,11,12}, Dimitrios Trichopoulos^{9,11,12}, Domenico Palli¹³, Sabina Sieri¹⁴, Rosario Tumino¹⁵, Carlotta Sacerdote¹⁶, Salvatore Panico¹⁷, H. Bas Bueno-de-Mesquita^{1,18,19,20}, Petra H. Peeters^{1,21}, Eiliv Lund²², Aurelie Nakamura²², Elisabete Weiderpass^{22,23,24,25}, J. Ramón Quirós²⁶, Antonio Agudo²⁷, Esther Molina-Montes^{28,29}, Nerea Larrañaga^{29,30}, Miren Dorronsoro^{29,31}, Lluís Cirera^{29,32}, Aurelio Barricarte^{29,33}, Åsa Olsson³⁴, Salma Butt³⁴, Annika Idahl^{35,36}, Eva Lundin³⁷, Nicholas J. Wareham³⁸, Timothy J. Key³⁹, Paul Brennan⁴⁰, Pietro Ferrari⁴⁰, Petra A. Wark¹, Teresa Norat¹, Amanda J. Cross¹ and Marc J. Gunter¹

Abstract

Background: Reproductive events are associated with important physiologic changes, yet little is known about how reproductive factors influence long-term health in women. Our objective was to assess the relation of reproductive characteristics with all-cause and cause-specific mortality risk.

Methods: The analysis was performed within the European Investigation into Cancer and Nutrition prospective cohort study, which enrolled >500,000 women and men from 1992 to 2000, who were residing in a given town/geographic area in 10 European countries. The current analysis included 322,972 eligible women aged 25–70 years with 99 % complete follow-up for vital status. We assessed reproductive characteristics reported at the study baseline including parity, age at the first birth, breastfeeding, infertility, oral contraceptive use, age at menarche and menopause, total ovulatory years, and history of oophorectomy/hysterectomy. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for mortality were determined using Cox proportional hazards regression models adjusted for menopausal status, body mass index, physical activity, education level, and smoking status/intensity and duration.

Results: During a mean follow-up of 12.9 years, 14,383 deaths occurred. The HR (95 % CI) for risk of all-cause mortality was lower in parous versus nulliparous women (0.80; 0.76–0.84), in women who had ever versus never breastfed (0.92; 0.87–0.97), in ever versus never users of oral contraceptives (among non-smokers; 0.90; 0.86–0.95), and in women reporting a later age at menarche (≥ 15 years versus < 12 ; 0.90; 0.85–0.96; P for trend = 0.038).

Conclusions: Childbirth, breastfeeding, oral contraceptive use, and a later age at menarche were associated with better health outcomes. These findings may contribute to the development of improved strategies to promote better long-term health in women.

Keywords: Age at menarche, Age at menopause, Breastfeeding, Mortality, Oral contraceptives, Parity

* Correspondence: m.merritt@imperial.ac.uk

¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
Full list of author information is available at the end of the article

Background

Reproductive events represent significant biological milestones in a woman's life and are associated with profound physiologic and endocrinologic changes. It is recognized that reproductive factors influence the risk of developing reproductive-related cancers; for example, age at menarche, use of oral contraceptives (OCs), parity, breastfeeding, and age at menopause are associated with risk of developing cancers of the breast, endometrium, and ovary [1–3]. Analyses of reproductive parameters in relation to all-cause and cause-specific mortality risk can provide further insights to understand how reproductive factors may influence the general long-term health of women.

Most [4–7], but not all [8], relevant studies reported that an earlier age at menarche was associated with a higher risk for all-cause mortality and/or selected cause-specific mortalities. Previous studies have reported no association [8–10], or an inverse association [11, 12], for ever versus never use of OCs with risk of all-cause mortality and/or mortality from cancer or cardiovascular disease. The association between parity and risk of all-cause and cause-specific mortality is uncertain due to inconsistent results across studies possibly because many [13–18], but not all [19–21], had incomplete information on other chronic disease risk factors which may confound the relationships, such as body mass index (BMI) and smoking habits. Although fewer studies have examined breastfeeding and mortality risk, recent analyses highlighted a lower risk of ischaemic heart disease [8] or circulatory/cardiovascular disease mortality [22, 23] among parous women who had ever versus never breastfed. Finally, some investigations reported that an early age at menopause was associated with a higher risk of mortality particularly from cardiovascular outcomes [24–27].

As reproductive factors are intricately linked, we evaluated several characteristics in relation to risk of all-cause and cause-specific mortality while adjusting for potential confounding factors, including BMI, physical activity, smoking, and education level. This study provides evidence from a large European prospective study on how common reproductive factors may influence the long-term health of women.

Methods

Study population

The European Prospective Investigation into Cancer and Nutrition (EPIC) study includes 518,408 participants (366,040 women) aged 25–70 years at enrolment (1992–2000). The cohort and data collection have been previously described [28, 29]. Briefly, study participants were recruited from the general population if they resided in a particular town or province in 23 centres in 10 European countries (Denmark, France, Germany,

Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom). Exceptions to this were the French cohort, which includes female members of the health insurance for teachers; components of the Italian (Ragusa and Turin) and Spanish cohorts that included members of local blood donor associations; Utrecht (the Netherlands) and Florence (Italy) cohorts, from where women attending population-based mammographic screening programs were recruited; Oxford (United Kingdom), where half of the cohort included “health conscious” participants from England, Wales, Scotland, and Northern Ireland who did not eat meat; and the cohorts of France, Norway, Utrecht (the Netherlands), and Naples (Italy) which included women only. Data on diet, lifestyle characteristics, and medical history were collected using baseline questionnaire and interview data. Informed consent was provided by all participants and ethical approval was obtained from the internal review board of the International Agency for Research on Cancer and from local ethics committees in the participating countries. The full list of all local ethics committees is provided in Additional file 1.

Exclusions at the study baseline were men; participants reporting prevalent diseases that could influence important confounders, diabetes ($n = 8,298$), myocardial infarction/heart attack ($n = 2,063$), angina ($n = 3,275$), stroke ($n = 1,920$), or cancer (except non-melanoma skin cancer; $n = 18,649$); participants who were missing a lifestyle questionnaire ($n = 536$), vital status ($n = 743$), or their date of death ($n = 216$); those who reported having never menstruated ($n = 37$) or were missing all of the following: age at menarche or menopause (postmenopausal women only), number of full term pregnancies (FTP), age at first and last FTP, OC use, and duration of breastfeeding ($n = 7,331$). Finally, 322,972 women were included in the analysis.

Exposure and covariate assessment

Reproductive characteristics assessed at the study baseline included parity (live/still births only), number of FTPs, age at first FTP, breastfeeding, infertility, OC ever use and current use, duration of OC use up until the time of recruitment, age at menarche, age at natural menopause, total ovulatory years, and history of oophorectomy or hysterectomy. Information on breastfeeding was only available for the first three and the last FTP, therefore the breastfeeding duration was calculated as the sum of these pregnancies and for women reporting >4 FTPs as the number of pregnancies multiplied by the mean duration of breastfeeding per child. Women with infertility were defined as those who had ever seen a doctor for fertility problems or if they reported a diagnosis, treatment, or surgery for fertility problems. OC formulations have changed over time; most notably, current OCs have

lower estrogen doses and may contain as little as 20 µg ethinyl estradiol, while OCs that were prescribed before 1970 were typically high dose preparations (~100 µg ethinyl estradiol) [30]. Data on OC formulation were not available in the EPIC study; therefore, we carried out sensitivity analyses of OC use after stratifying by calendar year of first use, before 1970 (high dose), 1970–79 (medium dose), and 1980 and later (low dose). The age at natural menopause was defined as the age at the last menstrual period and participants who reported a surgical menopause (due to hysterectomy or oophorectomy) that occurred before reaching their age at natural menopause or participants missing the date of their surgical menopause were excluded from this analysis. Age at menopause was categorized consistently with previous EPIC study reports [31, 32] and the largest category (46–50 years) was set as the referent group. Ovulatory years were calculated as the difference between a participant's age at menopause (postmenopausal) or their age at recruitment (premenopausal or perimenopausal/unknown menopause), and their age at menarche, minus the length of time that a woman was pregnant or using OCs. Anthropometric data [33], physical activity incorporating occupational and recreational activities [34], smoking status/intensity and duration, marital status, and education level at the study baseline also were assessed.

Documentation of mortality endpoints

Follow-up of study subjects for vital status, cause, and date of death commenced in the mid-1990s and the current study uses the most recent data from the follow-up cycle completed in 2010. Vital status data were collected using record linkages with cancer registries, boards of health, and death indices in Denmark, Italy (except Naples), the Netherlands, Norway, Spain, Sweden, and the United Kingdom or through active follow-up (inquiries by mail or telephone to participants, municipal registries, regional health departments, physicians, and hospitals) in Germany, Greece, Naples, Italy, and France following standardized guidelines for the collection of endpoint data in the EPIC Study (IARC, 1998, unpublished). Procedures to ensure that valid and complete active follow-up data were collected were previously described for the German [35], Greek [36], Naples [37], and French [38] subcohorts. Causes of death were coded according to the 10th revision of the International Statistical Classification of Diseases, Injuries, and Causes of Death. For cause-specific mortality analyses, deaths were grouped into categories representing the most common causes of death (cancer, circulatory disease), and categories were further subdivided into the most commonly occurring disease subgroups; breast cancer, cerebrovascular, and ischaemic heart disease.

Statistical analyses

Cox proportional hazards regression modelling using age as the underlying time metric with the subjects' age at recruitment as the entry time and their age at death or censoring, emigration, or last complete follow-up, whichever occurred first, as the exit time, were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for the associations between reproductive characteristics and mortality risk. To account for differences across study centres in the timing to report causes of death, in cause-specific analyses the follow-up dates were truncated to when 80 % of the causes of death at each centre were known; specifically, June 2005 (Cambridge), December 2006 (France, Varese, Turin, Naples, Granada, Murcia, Malmo, Denmark), December 2007 (Florence, San Sebastian, Umeå, Norway), December 2008 (Ragusa, Asturias, Navarra, the Netherlands), and June 2009 (Oxford). For Germany and Greece, the end of the follow-up was the last known date of contact or death; this extended to July 2010 (Germany) and December 2009 for Greece.

Multivariate analyses were adjusted for important confounders that were selected *a priori*; menopausal status, BMI, physical activity, education level, and smoking status/intensity and duration while including an indicator category for missing data, and all models were stratified by the study centre and the participant's age at recruitment. Sensitivity analyses that excluded individuals with missing values for these covariates showed similar results; these data are not presented here. We examined alcohol intake as a potential confounder by classifying individuals into quartiles based on their levels of ethanol intake in grams per day but did not include this in the final models because the HRs were not altered by >10 % [39]. Continuous variables were modelled to calculate a *P* for trend.

We carried out further separate analyses of all-cause mortality risk to examine the following associations: parity (parous versus nulliparous) when stratifying by marital status (never, ever married); number of FTPs when stratifying by BMI (<25 kg/m², ≥25), since having more children may lead to weight gain; age at menarche after stratifying by BMI because an early age at menarche has been linked to a higher BMI in adulthood; breastfeeding duration after stratifying by the number of FTPs (1–2 FTPs, >2); and age at menopause and ever use of OCs were assessed separately after stratifying by smoking status. In each of these models, a *P* for statistical interaction was calculated using a likelihood ratio test to compare multivariate models with and without multiplicative interaction terms. Additional sensitivity analyses were conducted after restricting to women who were postmenopausal at recruitment, or without excluding participants who reported prevalent conditions. In analyses

of age at menopause, we conducted further sensitivity analysis of breast cancer mortality without excluding women who had a surgically-induced menopause. The proportional hazards assumption was verified using the Grambsch and Therneau [40] method. A two tailed $P < 0.05$ was considered statistically significant. Analyses were performed using the survival package [41] in R (version 3.0.2) [42].

Results

Baseline characteristics

After a mean follow-up of 12.9 (SD = 2.3) years, 14,383 all-cause deaths were identified, including 5,938 cancer deaths and 2,404 deaths from circulatory diseases. The distribution of most reproductive characteristics was similar across countries (Table 1) although there were differences in the proportion of women who used OCs (11–40 % in Greece, Spain, and Italy versus ≥ 58 % in other countries). We also observed a slightly lower proportion of parous women in the Netherlands and the United Kingdom. In the French cohort, fewer parous women had ever breastfed (72 % versus ≥ 81 % in other countries).

Association of reproductive factors with all-cause mortality

Parity was associated with a lower risk of all-cause mortality (parous versus nulliparous; HR = 0.80; CI, 0.76–0.84; Table 2). Having an early or late age at first FTP versus having a first FTP at age 26–30 was associated with a higher risk for all-cause mortality (first FTP ≤ 20 : HR = 1.10; CI, 1.04–1.17; first FTP ≥ 31 : HR = 1.08; CI, 1.01–1.16). Among parous women, ever versus never breastfeeding was inversely associated with risk of all-cause mortality (HR = 0.92; CI, 0.87–0.97). In contrast, there was no association with the number of FTPs or breastfeeding duration (P for trend ≥ 0.79).

Having a late versus early age at menarche was associated with a lower risk of all-cause mortality; women who underwent menarche at age ≥ 15 years compared with age < 12 had a 10 % reduction in risk of death (HR = 0.90; CI, 0.85–0.96) and there was an inverse trend across age at menarche categories (P for trend = 0.038). Having an early age at natural menopause was associated with a higher risk of all-cause mortality (≤ 45 years versus 46–50; HR = 1.09; CI, 1.01–1.17), while overall there was a suggestion of lower risk with a later age at menopause (P for trend < 0.001). There was no association between infertility, total ovulatory years, oophorectomy, or hysterectomy with risk of all-cause mortality.

In stratified analyses, an inverse association between ever versus never use of OCs and risk of all-cause mortality was observed only in never/former smokers (HR = 0.90; CI, 0.86–0.95; $n = 3,736$ deaths were observed among ever users of OCs), but not current smokers (OC ever

versus never use; HR = 0.98; CI, 0.91–1.05; $n = 2,076$ deaths occurred in ever users of OCs, P for interaction = 0.0021); analyses of OCs and mortality risk were therefore restricted to participants who were never/former smokers. There was a similar lower risk of all-cause mortality in former users and current users of OCs at the study baseline, although the finding for current users was non-significant possibly due to the small number of deaths ($n = 140$) in this category. The lowered risk of all-cause mortality associated with ever use of OCs was observed across all categories grouped by calendar year of first use (before 1970: HR = 0.89; CI, 0.84–0.95; 1970s: HR = 0.89; CI, 0.83–0.95; 1980s and later: HR = 0.84; CI, 0.71–0.99; data not shown). In contrast, there was no association with the duration of OC use among ever users of OCs irrespective of smoking status (P for interaction = 0.283 for never/former and current smokers).

The inverse association between having a late age at menarche (age ≥ 15 years versus < 12) and risk of all-cause mortality was only observed in women with a BMI ≥ 25 kg/m² (HR = 0.82; CI, 0.75–0.89; P for trend = 0.0034). In contrast, there was no association for participants with a BMI < 25 kg/m² (HR = 0.98; CI, 0.90–1.07; P for trend = 0.58; P for interaction = 0.016). Results from the stratified analyses are detailed in Additional file 2. The higher incidence of all-cause mortality among women with an early age at menopause (menopause age ≤ 45 years versus 46–50) was restricted to former and current smokers (HR = 1.22; CI, 1.10–1.35; P for trend < 0.001), while there was no association in never smokers (HR = 1.02; CI, 0.91–1.13; P for trend = 0.35; P for interaction = 0.012). There was no difference in the risk associations for all-cause mortality in analyses of parity when stratifying by marital status, for the number of FTPs according to BMI, or with breastfeeding duration by the number of FTPs (P for interaction ≥ 0.34). In sensitivity analyses, we observed similar results for all-cause mortality analyses when restricting analyses to postmenopausal women only, or when participants who reported prevalent conditions (diabetes, heart conditions, or cancer) were not excluded (data not shown). In sensitivity analyses of age at menopause without excluding women who reported a surgically-induced menopause in relation to breast cancer mortality, we observed similar results to those reported for age at natural menopause (data not shown).

Cancer mortality

Risk of total cancer mortality was lower in parous versus nulliparous women (HR = 0.87; CI, 0.80–0.93) and with a later age at menarche (age ≥ 15 years versus < 12 ; HR = 0.89; CI, 0.81–0.98; P for trend = 0.042; Table 3). Among parous women, having two or three FTPs versus one was associated with a lower risk of total cancer mortality (e.g. 3 FTPs versus 1; HR = 0.89; CI, 0.81–0.97), but

Table 1 Age standardized^a reproductive and lifestyle characteristics of the EPIC study population by country

	Total	Denmark	France	Germany	Greece	Italy	Norway	Spain	Sweden	The Netherlands	United Kingdom
No. of participants	322,972	27,887	66,878	26,766	13,893	30,008	35,215	23,828	19,930	26,223	52,344
Number of deaths	14,383	1,879	2,913	671	527	834	756	625	1,583	1,419	3,176
Mean (SD)											
Age at recruitment, years	50.3 (9.6)	56.2 (4.4)	52.1 (6.6)	48.1 (8.9)	51.6 (12.3)	50.0 (8.0)	47.6 (4.3)	47.5 (8.3)	54.9 (8.1)	50.2 (11.6)	47.1 (14.1)
Duration OC use, years ^{b,c}	7.7 (7.3)	9.4 (6.4)	7.4 (6.3)	12.4 (8.5)	2.5 (2.8)	4.1 (4.8)	5.0 (4.5)	3.7 (3.6)	9.7 (8.3)	9.9 (7.3)	7.6 (6.8)
Number of FTPs ^{c,d,e}	2.3 (1.0)	2.2 (0.6)	2.3 (0.9)	2.0 (0.9)	2.3 (1.0)	2.1 (0.9)	2.4 (0.8)	2.8 (1.3)	2.2 (0.9)	2.6 (1.2)	2.3 (1.0)
Age at first FTP ^{c,d}	24.9 (4.4)	23.8 (3.1)	24.9 (3.7)	24.2 (4.4)	24.1 (4.7)	25.8 (4.3)	24.0 (3.7)	24.9 (3.8)	24.6 (4.1)	25.4 (4.3)	25.6 (4.9)
Breastfeeding, months ^{c,f}	9.6 (10.6)	9.4 (6.3)	5.5 (5.2)	5.4 (6.4)	13.7 (16.3)	9.1 (8.5)	13.6 (9.5)	13.1 (12.8)	9.7 (7.3)	6.6 (6.9)	9.9 (12.9)
Age at menarche, years ^c	13.1 (1.5)	13.7 (1.2)	12.9 (1.3)	13.2 (1.5)	13.2 (1.6)	12.6 (1.5)	13.3 (1.1)	13.0 (1.6)	13.3 (1.5)	13.3 (1.6)	12.9 (1.6)
Age at menopause, years ^{c,g}	49.4 (4.4)	49.9 (3.9)	50.2 (4.3)	50.1 (3.2)	48.0 (4.7)	49.2 (4.1)	48.6 (3.3)	48.8 (4.4)	–	49.1 (4.5)	49.2 (4.6)
BMI, kg/m ²	24.9 (4.4)	25.5 (3.2)	23.0 (3.2)	25.7 (4.6)	28.5 (5.2)	25.6 (4.3)	24.5 (3.1)	28.5 (4.6)	24.7 (4.2)	25.1 (4.2)	24.6 (4.2)
Percentages											
Ever use OCs ^c	59	58	60	80	11	40	60	36	61	76	68
Parous ^c	85	88	90	86	90	87	92	89	86	81	78
Ever breastfed ^{c,e}	85	93	72	84	88	84	94	89	95	81	83
Infertility ^{c,h}	5	–	6	1	4	6	–	4	–	3	5
Premenopausal	35	7	27	37	38	38	23	42	27	37	38
Postmenopausal	43	73	45	42	45	43	44	41	48	40	43
Surgical menopause ⁱ	3	5	3	3	6	4	0	6	0	2	4
Perimenopausal/unknown menopause	19	16	25	17	12	15	32	11	26	20	15
Hysterectomy ^{c,j}	11	14	10	16	9	9	5	10	–	16	16
Oophorectomy ^{c,j}	7	10	6	8	8	8	1	9	–	8	8
Current smoker ^{c,k}	20	31	9	18	19	26	32	15	25	29	11
Marital status: single	9	0	17	8	4	6	0	0	7	12	9
Ever married ^l	72	0	80	92	96	93	81	0	92	87	90
Marital status: unknown	19	100	4	0	0	1	19	100	0	0	0

BMI, Body mass index; FTP, Full term pregnancy; OCs, Oral contraceptives

^aAll variables (with the exception of age) were age standardized using 5-year age groups to the age distribution of the entire study population

^bAmong ever users of OCs

^cVariables had missing data (≤ 4.2 % missing) with the exception of ever breastfed among parous (6.1 % missing), duration OC use in ever users (9.5 % missing), and age at natural menopause (26.3 % missing)

^dFTPs includes live births and stillbirths

^eAmong parous women

^fAmong women with a FTP who had ever breastfed

^gPostmenopausal women only; exclusions were participants from Sweden (no data for hysterectomy/oophorectomy), those who reported a surgical menopause (hysterectomy/oophorectomy), or if information on surgical menopause was not available

^hDenmark, Sweden, Norway and the Bilthoven study centre were excluded since data were not available

ⁱDefined as bilateral oophorectomy only

^jSweden was excluded from these comparisons because data were not available

^kCurrent smoking included smoking of cigarettes, pipes, or cigars

^lEver married includes living together, divorced, separated, and widowed

Table 2 Association of reproductive characteristics with all-cause mortality in the EPIC study

Variable	Value	Cases / non-cases	Model 1 HR ^a (95 % CI)	Model 2 HR ^b (95 % CI)
Parous	No	2,220 / 45,746	1.00 (reference)	1.00 (reference)
	Yes	11,757 / 254,871	0.80 (0.76–0.83)	0.80 (0.76–0.84)
Number of FTPs ^c	1	2,307 / 45,881	1.00 (reference)	1.00 (reference)
	2	5,026 / 122,430	0.87 (0.83–0.91)	0.91 (0.86–0.96)
	3	2,529 / 56,316	0.83 (0.79–0.88)	0.87 (0.82–0.92)
	4	1,047 / 16,278	0.97 (0.90–1.04)	0.98 (0.91–1.06)
	5	350 / 4,448	0.97 (0.87–1.09)	0.97 (0.86–1.09)
	≥6	237 / 2,290	1.09 (0.95–1.25)	1.08 (0.94–1.24)
	<i>P</i> for trend ^d			0.91
Age at first FTP, years ^c	≤20	1,812 / 37,390	1.30 (1.23–1.38)	1.10 (1.04–1.17)
	21–23	3,121 / 68,203	1.13 (1.07–1.19)	1.05 (1.00–1.11)
	24–25	2,173 / 49,889	1.02 (0.97–1.08)	1.00 (0.95–1.06)
	26–30	3,287 / 72,649	1.00 (reference)	1.00 (reference)
	≥31	1,281 / 25,749	1.08 (1.01–1.15)	1.08 (1.01–1.16)
Breastfeeding ^c	Never	1,721 / 36,691	1.00 (reference)	1.00 (reference)
	Ever	9,148 / 202,910	0.88 (0.83–0.93)	0.92 (0.87–0.97)
Breastfeeding, months ^e	≤1	949 / 20,021	1.00 (reference)	1.00 (reference)
	>1 to ≤3	1,753 / 39,935	1.01 (0.93–1.09)	1.01 (0.93–1.09)
	>3 to ≤6	1,846 / 41,685	0.94 (0.87–1.02)	0.97 (0.89–1.05)
	>6 to ≤12	2,224 / 47,802	0.90 (0.83–0.98)	0.95 (0.88–1.03)
	>12 to ≤18	986 / 23,319	0.81 (0.74–0.89)	0.88 (0.80–0.97)
	>18	1,276 / 27,949	0.88 (0.80–0.96)	0.97 (0.89–1.07)
<i>P</i> for trend ^d			0.013	0.85
Infertility ^f	No	8,958 / 199,770	1.00 (reference)	1.00 (reference)
	Yes	360 / 9,869	1.06 (0.95–1.18)	1.06 (0.95–1.18)
OC use in never or former smokers at baseline ^g	Never	6,379 / 100,292	1.00 (reference)	1.00 (reference)
	Ever	3,736 / 140,642	0.90 (0.85–0.94)	0.90 (0.86–0.95)
	Former ^h	3,475 / 122,414	0.89 (0.85–0.94)	0.90 (0.86–0.95)
	Current ^h	140 / 12,959	0.89 (0.74–1.07)	0.92 (0.76–1.11)
Duration OC use, years ^{g,i}	≤1	679 / 25,490	1.00 (reference)	1.00 (reference)
	>1 to <5	721 / 30,600	0.99 (0.89–1.10)	0.99 (0.89–1.11)
	5 to <10	705 / 30,859	0.95 (0.85–1.06)	0.96 (0.86–1.07)
	10 to <15	616 / 21,267	1.05 (0.94–1.18)	1.06 (0.94–1.18)
	≥15	526 / 18,583	1.02 (0.90–1.15)	1.02 (0.91–1.16)
	<i>P</i> for trend ^d			0.36
Age at menarche, years	<12	1,977 / 45,763	1.00 (reference)	1.00 (reference)
	12	2,714 / 65,654	0.92 (0.86–0.97)	0.95 (0.89–1.01)
	13	3,378 / 79,701	0.88 (0.84–0.94)	0.92 (0.87–0.98)
	14	3,224 / 66,159	0.89 (0.84–0.95)	0.93 (0.88–0.98)
	≥15	2,774 / 47,743	0.88 (0.82–0.93)	0.90 (0.85–0.96)
	<i>P</i> for trend ^d			0.004
Age at natural menopause, years ^j	≤45	1,080 / 12,399	1.15 (1.07–1.24)	1.09 (1.01–1.17)
	46–50	2,427 / 32,488	1.00 (reference)	1.00 (reference)
	51–52	1,064 / 14,537	0.88 (0.82–0.95)	0.91 (0.85–0.99)

Table 2 Association of reproductive characteristics with all-cause mortality in the EPIC study (*Continued*)

	53–55	1,003 / 12,753	0.86 (0.80–0.93)	0.92 (0.85–0.99)
	>55	339 / 3,287	0.90 (0.80–1.01)	0.95 (0.85–1.07)
	<i>P</i> for trend ^d		<0.001	<0.001
Total ovulatory lifespan, years ^{k,l}	0–22	1,180 / 56,387	1.00 (reference)	1.00 (reference)
	22–29	1,621 / 53,629	0.96 (0.89–1.05)	0.99 (0.91–1.07)
	29–34	2,148 / 52,270	0.92 (0.84–0.99)	0.96 (0.89–1.04)
	≥34	3,115 / 51,923	0.89 (0.82–0.97)	0.98 (0.91–1.06)
	<i>P</i> for trend ^d		0.004	0.86
Oophorectomy ^l	No	11,167 / 266,535	1.00 (reference)	1.00 (reference)
	Yes	1,202 / 18,603	1.05 (0.98–1.11)	1.01 (0.93–1.10)
Hysterectomy ^l	No	10,606 / 257,298	1.00 (reference)	1.00 (reference)
	Yes	1,972 / 30,608	1.01 (0.96–1.06)	1.00 (0.94–1.05)

FTP, Full term pregnancy; OCs, Oral contraceptives

^aCox regression stratified by age (continuous) and study centre

^bCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical postmenopausal [bilateral oophorectomy]), body mass index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m²), physical activity index (inactive [Ref], moderately inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/professional school, secondary school/longer education including university, or unknown), smoking status/intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/day, former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40, 40+ years, unknown), and stratified by age and study centre

^cRestricted to parous women. A FTP was defined as live births and stillbirths

^d*P* for trend values are based on continuous variables: the number of FTPs was modelled as 1 to ≥10; age at menarche as ≤8, 9–19, ≥20; age at menopause as <35, 35–60, >60

^eAmong parous women who had ever breastfed (sum of all FTPs)

^fDenmark, Sweden, Norway, and the Bilthoven (Netherlands) study centre were excluded since data were not available

^gRestricted to participants who were never or former smokers, therefore models were adjusted for the same factors^b and a modified smoking status/intensity variable (never [Ref], former quit ≤10 years, former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)

^hDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use

ⁱAmong ever users of OCs

^jAmong postmenopausal women; excluded participants from Sweden (no data for hysterectomy/oophorectomy), those who reported a surgical menopause (hysterectomy and/or unilateral/bilateral oophorectomy), or if information on surgical menopause was missing

^kThe total ovulatory lifespan is the difference between the age at natural menopause and the age at menarche for postmenopausal women, or the difference between the age at recruitment and the age at menarche for premenopausal/perimenopausal/unknown menopausal status women, minus the amount of time that a woman was pregnant (number of full term pregnancies × nine months) and/or used OCs

^lSweden was excluded from these comparisons (no data for hysterectomy/oophorectomy), therefore age at natural menopause could not be determined

having more than three FTPs versus one was not associated with risk. Among never/former smokers, we observed a lower risk of total cancer mortality in ever versus never users of OCs (HR = 0.91; CI, 0.85–0.98), while there was no association with OC use in participants who were current smokers at baseline (ever versus never users of OCs; HR = 1.00; CI, 0.90–1.12). In analyses of breast cancer mortality, there was a strong decreased risk in parous versus nulliparous women (HR = 0.70; CI, 0.58–0.85) and a trend of lower mortality risk with a higher number of FTPs (*P* for trend = 0.012). There was no association with other reproductive characteristics although the number of breast cancer deaths (*n* = 749) was limited.

Circulatory disease mortality

Reproductive characteristics that were inversely associated with risk of death from circulatory disease included parity (parous versus nulliparous; HR = 0.86; CI, 0.76–0.96), breastfeeding (ever versus never breastfed; HR = 0.80; CI, 0.70–0.91), and a late age at menarche

(≥15 years versus <12; HR = 0.83; CI, 0.72–0.96; Table 4). Never/former smokers at baseline who had ever versus never used OCs had a lower risk of circulatory disease death (HR = 0.85; CI, 0.75–0.97). In contrast, among current smokers at baseline, there was no association with ever use of OCs (HR = 0.98; CI, 0.81–1.17). There was a small but non-significant increase in risk of circulatory disease death for current OC users as compared with never users of OCs at baseline (HR = 1.48; CI, 0.90–2.43; based on *n* = 22 deaths). In sub-analyses of ischaemic heart disease mortality, we observed strong inverse associations with parity (parous versus nulliparous women), breastfeeding (ever versus never breastfed), and a suggestive inverse association with a late versus early age at natural menopause. In analyses of death from cerebrovascular disease, there were non-significant inverse associations with a late versus early age at menarche, and in ever versus never users of OCs (former/never smokers only). In contrast, non-smoking participants who reported current OC use at the study baseline had a higher risk of cerebrovascular disease death

Table 3 Association of reproductive characteristics with total cancer and breast cancer mortality in the EPIC study

ICD-10 code	Variable	Value	Total cancer (n = 5,938)		Breast cancer (n = 749)	
			C00–D48	HR ^a (95 % CI)	C50	HR ^a (95 % CI)
Parous	Yes		4,973 / 261,634	0.87 (0.80–0.93)	598 / 266,009	0.70 (0.58–0.85)
Number of FTPs ^{b,c}	1		944 / 47,240	1.00 (reference)	135 / 48,049	1.00 (reference)
	2		2,164 / 125,284	0.91 (0.84–0.98)	268 / 127,180	0.74 (0.60–0.92)
	3		1,069 / 57,773	0.89 (0.81–0.97)	119 / 58,723	0.70 (0.54–0.90)
	4		442 / 16,880	1.05 (0.93–1.18)	55 / 24,591	0.68 (0.49–0.95)
	5		118 / 4,680	0.86 (0.71–1.05)		
	≥6		88 / 2,438	1.11 (0.89–1.39)		
	<i>P</i> for trend ^d			0.85		0.012
Age at first FTP, years ^b	≤20		781 / 38,420	1.03 (0.94–1.14)	90 / 39,111	0.89 (0.68–1.16)
	21–23		1,267 / 70,055	0.97 (0.90–1.05)	135 / 71,187	0.79 (0.63–0.99)
	24–25		915 / 51,141	0.95 (0.87–1.03)	114 / 51,942	0.91 (0.72–1.15)
	26–30		1,446 / 74,481	1.00 (reference)	187 / 75,740	1.00 (reference)
	≥31		531 / 26,496	1.06 (0.96–1.17)	70 / 26,957	1.05 (0.79–1.39)
Breastfeeding ^e	Ever		3,964 / 208,077	0.99 (0.91–1.08)	484 / 211,557	1.01 (0.79–1.29)
Breastfeeding, months ^f	≤1		399 / 20,571	1.00 (reference)	58 / 20,912	1.00 (reference)
	>1 to ≤3		768 / 40,917	0.96 (0.85–1.09)	102 / 41,583	0.87 (0.62–1.21)
	>3 to ≤6		783 / 42,744	0.92 (0.81–1.04)	82 / 43,445	0.68 (0.48–0.96)
	>6 to ≤12		965 / 49,056	0.93 (0.83–1.05)	101 / 49,920	0.69 (0.49–0.97)
	>12 to ≤18		434 / 23,868	0.87 (0.76–1.00)	63 / 24,239	0.88 (0.60–1.27)
	>18		579 / 28,644	1.04 (0.90–1.19)	74 / 29,149	0.94 (0.65–1.37)
	<i>P</i> for trend ^d			0.23		0.35
OC use in never or former smokers at baseline ^g	Never		2,376 / 104,288	1.00 (reference)	257 / 106,407	1.00 (reference)
	Ever		1,775 / 142,587	0.91 (0.85–0.98)	313 / 144,049	1.11 (0.91–1.35)
	Former ^h		1,656 / 124,219	0.91 (0.85–0.98)	291 / 125,584	1.12 (0.92–1.36)
	Current ^h		78 / 13,019	0.93 (0.73–1.20)	18 / 13,079	0.87 (0.50–1.50)
Duration of OC use, years ^{g,i}	≤1		325 / 25,843	1.00 (reference)	53 / 26,115	1.00 (reference)
	>1 to <5		340 / 30,979	0.96 (0.82–1.12)	64 / 31,255	1.00 (0.69–1.45)
	5 to <10		372 / 31,188	1.06 (0.91–1.23)	59 / 31,501	0.94 (0.64–1.37)
	10 to <15		305 / 21,576	1.09 (0.92–1.28)	63 / 21,818	1.33 (0.91–1.94)
	≥15		277 / 18,825	1.07 (0.90–1.27)	53 / 19,049	1.22 (0.81–1.83)
	<i>P</i> for trend ^d				0.195	
Age at menarche, years	<12		811 / 46,926	1.00 (reference)	98 / 47,639	1.00 (reference)
	12		1,147 / 67,220	0.97 (0.89–1.06)	162 / 68,205	1.17 (0.91–1.51)
	13		1,380 / 81,686	0.91 (0.83–0.99)	164 / 82,902	0.93 (0.72–1.20)
	14		1,365 / 68,009	0.95 (0.87–1.04)	198 / 69,176	1.27 (0.99–1.63)
	≥15		1,125 / 49,388	0.89 (0.81–0.98)	114 / 50,399	0.89 (0.67–1.18)
	<i>P</i> for trend ^d				0.042	
Age at natural menopause, years ^j	≤45		371 / 13,105	0.97 (0.86–1.10)	30 / 13,446	0.68 (0.45–1.03)

Table 3 Association of reproductive characteristics with total cancer and breast cancer mortality in the EPIC study (*Continued*)

46–50	988 / 33,921	1.00 (reference)	120 / 34,789	1.00 (reference)
51–52	448 / 15,151	0.98 (0.88–1.10)	43 / 15,556	0.80 (0.56–1.14)
53–55	448 / 13,307	1.08 (0.96–1.21)	53 / 13,702	1.03 (0.73–1.45)
>55	141 / 3,483	1.12 (0.93–1.34)	13 / 3,611	0.87 (0.47–1.61)
<i>P</i> for trend ^d		0.080		0.37

FTP, Full term pregnancy; OCs, Oral contraceptives; ICD-10, International Statistical Classification of Diseases Injuries and Causes of Death (10th revision)

^aCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical postmenopausal (bilateral oophorectomy)), body mass index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m²), physical activity index (inactive [Ref], moderately inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/professional school, secondary school/longer education including university, or unknown), smoking status/intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/day, former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40, 40+ years, unknown), and stratified by age (continuous) and study centre

^bFTP includes live births and stillbirths

^cFor breast cancer the top categories were combined as indicated due to small numbers

^d*P* for trend values are based on continuous variables: the number of FTPs was modelled as 1 to ≥10; age at menarche as ≤8, 9–19, ≥20; age at menopause as <35, 35–60, >60

^eAmong parous women

^fAmong parous women who had ever breastfed (sum of all FTPs)

^gRestricted to participants who were never or former smokers, therefore models were adjusted for the same factors^a and a modified smoking status/intensity variable (never [Ref], former quit ≤10 years, former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)

^hDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use

ⁱAmong ever users of OCs

^jAmong postmenopausal women; exclusions included participants from Sweden (no data for hysterectomy/oophorectomy), those who had a surgical menopause (hysterectomy and/or oophorectomy), or if information on surgical menopause was missing

(HR = 2.62; CI, 1.30–5.26), but this finding was based on a small number ($n = 13$) of deaths; there were too few current OC users who were also current smokers at the study baseline to evaluate this subgroup.

Discussion

In a large and comprehensive prospective study representing data from 10 European countries, we observed that, after controlling for factors known to influence mortality risk (such as BMI, smoking habits and physical activity), childbirth, breastfeeding among parous women, ever use of OCs among non-smokers, a later age at menopause, and a later age at menarche were associated with a significantly lower risk of all-cause mortality. Most of these associations were also apparent when we considered cause-specific deaths from total cancer and ischaemic heart disease. Importantly, these reproductive factors are common exposures and with a better understanding of how these factors may influence long-term health this information may assist in the development of new clinical strategies for the improvement of women's health.

The inverse association for parous as compared with nulliparous women with risk of all-cause, total cancer, breast cancer, and ischaemic heart disease mortality is consistent with previous studies [13–17, 43, 44]. It is possible that other underlying factors may explain the association between parous versus nulliparous women; for example, some women may be nulliparous because they were chronically unwell. However, our data did not suggest that nulliparous women had poorer health as their BMI, physical activity levels, and smoking status

were similar to parous women. Notable differences were that a higher proportion of nulliparous women had obtained a higher education level and fewer nulliparous women had ever married. Among parous women, we observed a trend of lower risk for breast cancer mortality with an increasing number of FTPs. In contrast, the number of FTPs was not associated with other mortality outcomes. It has been suggested that having ≥4 births may increase a mother's risk of circulatory disease mortality [21], possibly by inducing hypertensive changes [45] and/or by increasing their body weight [46]. However, in a study of highly parous women in Northern Finland, only women with ≥10 births (versus 2–4) had a higher risk of mortality from haemorrhagic stroke [20]. Consistent with previous studies [8, 23], we observed that parous women who had ever breastfed had a lower risk of mortality from all-causes and ischaemic heart disease. Prior studies have observed that women who never breastfed [47] and/or had a shorter lactation period [22, 48] had a higher risk to develop hypertension. Similar to prior reports [4–6, 8], we observed that a later age at menarche was associated with a lower risk of all-cause, total cancer, and circulatory mortality. Having an earlier age at menarche has been associated with elevated blood pressure and glucose intolerance [49], increased body fat in early adulthood [50], or obesity in adulthood [51], all of which could explain the possible link between the age at menarche and risk of mortality outcomes later in life. We also observed that an early age at menopause was associated with a higher risk of all-cause mortality, but this association was attenuated and non-significant in never smokers, which

Table 4 Association of reproductive characteristics with mortality from circulatory diseases in the EPIC study

ICD-10 codes	Variable	Value	Circulatory disease (n = 2,404)		Cerebrovascular disease (n = 808)		Ischaemic heart disease (n = 732)	
			100–I99	HR ^a (95 % CI)	I60–I69	HR ^a (95 % CI)	I20–I25	HR ^a (95 % CI)
	Parous	Yes	1,970 / 264,637	0.86 (0.76–0.96)	655 / 265,952	0.93 (0.76–1.13)	598 / 266,009	0.79 (0.65–0.97)
	Number of FTPs ^b	1	374 / 47,810	1.00 (reference)	114 / 48,070	1.00 (reference)	117 / 48,067	1.00 (reference)
		2	799 / 126,649	0.92 (0.81–1.04)	281 / 127,167	1.06 (0.85–1.32)	240 / 127,208	0.91 (0.73–1.14)
		3	431 / 58,411	0.88 (0.76–1.02)	135 / 58,707	0.90 (0.70–1.17)	139 / 58,703	0.93 (0.73–1.20)
		4	198 / 17,124	0.95 (0.79–1.13)	66 / 17,256	1.03 (0.75–1.41)	48 / 17,274	0.74 (0.52–1.05)
		5	63 / 4,735	0.85 (0.65–1.12)	21 / 4,777	0.92 (0.57–1.48)	18 / 4,780	0.78 (0.47–1.29)
		≥6	62 / 2,464	1.13 (0.85–1.50)	23 / 2,503	1.49 (0.93–2.39)	19 / 2,507	1.12 (0.67–1.88)
		<i>P</i> for trend ^c		0.85		0.42		0.29
	Age at first FTP, years ^d	≤20	304 / 38,897	1.15 (0.99–1.34)	97 / 39,104	1.14 (0.86–1.50)	105 / 39,096	1.14 (0.86–1.51)
		21–23	497 / 70,825	1.11 (0.98–1.26)	150 / 71,172	0.96 (0.76–1.23)	140 / 71,182	0.96 (0.74–1.24)
		24–25	359 / 51,697	1.05 (0.92–1.20)	122 / 51,934	1.00 (reference)	106 / 51,950	1.00 (reference)
		26–30	557 / 75,370	1.00 (reference)	199 / 75,728	0.97 (0.78–1.23)	166 / 75,761	0.99 (0.77–1.26)
		≥31	237 / 26,790	1.06 (0.90–1.23)	79 / 26,948	0.90 (0.67–1.21)	74 / 26,953	1.10 (0.81–1.49)
	Breastfeeding ^d	Ever	1,534 / 210,507	0.80 (0.70–0.91)	526 / 211,515	0.94 (0.74–1.21)	445 / 211,596	0.69 (0.54–0.87)
	Breastfeeding, months ^e	≤1	135 / 20,835	1.00 (reference)	38 / 20,932	1.00 (reference)	41 / 20,929	1.00 (reference)
		>1 to ≤3	282 / 41,403	1.16 (0.94–1.43)	101 / 41,584	1.47 (1.00–2.14)	86 / 41,599	1.22 (0.83–1.79)
		>3 to ≤6	276 / 43,251	1.05 (0.85–1.30)	93 / 43,434	1.20 (0.82–1.77)	91 / 43,436	1.22 (0.83–1.79)
		>6 to ≤12	359 / 49,662	1.02 (0.83–1.26)	115 / 49,906	1.10 (0.75–1.60)	102 / 49,919	0.99 (0.68–1.45)
		>12 to ≤18	184 / 24,118	0.98 (0.78–1.23)	69 / 24,233	1.18 (0.78–1.77)	51 / 24,251	0.94 (0.61–1.44)
		>18	287 / 28,936	1.04 (0.83–1.31)	110 / 29,113	1.28 (0.85–1.90)	71 / 29,152	0.92 (0.60–1.40)
		<i>P</i> for trend ^c		0.48		0.076		0.153
	OC use in never or former smokers at baseline ^f	Never	1,274 / 105,390	1.00 (reference)	467 / 106,197	1.00 (reference)	352 / 106,312	1.00 (reference)
		Ever	427 / 143,935	0.85 (0.75–0.97)	144 / 144,218	0.80 (0.64–1.01)	102 / 144,260	0.87 (0.67–1.12)
		Former ^g	397 / 125,478	0.84 (0.74–0.96)	129 / 125,746	0.78 (0.62–0.98)	100 / 125,775	0.87 (0.67–1.13)
		Current ^{g,h}	22 / 13,075	1.48 (0.90–2.43)	13 / 13,084	2.62 (1.30–5.26)	2 / 13,095	-
	Duration of OC use, years ^{fi}	≤1	72 / 26,096	1.00 (reference)	23 / 26,145	1.00 (reference)	21 / 26,147	1.00 (reference)
		>1 to <5	72 / 31,247	0.95 (0.68–1.33)	23 / 31,296	0.95 (0.52–1.73)	21 / 31,298	0.97 (0.52–1.83)
		5 to <10	80 / 31,480	0.98 (0.70–1.36)	34 / 31,526	1.40 (0.80–2.44)	14 / 31,546	0.58 (0.29–1.16)
		10 to <15	84 / 21,797	1.22 (0.88–1.70)	22 / 21,859	1.08 (0.59–2.00)	22 / 21,859	1.09 (0.58–2.05)
		≥15	70 / 19,032	1.14 (0.80–1.62)	30 / 19,072	1.63 (0.91–2.94)	15 / 19,087	0.96 (0.48–1.94)
		<i>P</i> for trend ^c		0.38		0.177		0.91

Table 4 Association of reproductive characteristics with mortality from circulatory diseases in the EPIC study (Continued)

Age at menarche, years	<12	325 / 47,412	1.00 (reference)	105 / 47,632	1.00 (reference)	107 / 47,630	1.00 (reference)
	12	411 / 67,956	0.84 (0.73–0.98)	132 / 68,235	0.80 (0.62–1.04)	123 / 68,244	0.80 (0.62–1.04)
	13	555 / 82,511	0.89 (0.77–1.02)	186 / 82,880	0.86 (0.67–1.09)	165 / 82,901	0.81 (0.63–1.03)
	14	559 / 68,815	0.91 (0.79–1.05)	189 / 69,185	0.88 (0.69–1.12)	164 / 69,210	0.80 (0.62–1.02)
	≥15	494 / 50,019	0.83 (0.72–0.96)	165 / 50,348	0.79 (0.61–1.02)	160 / 50,353	0.80 (0.62–1.03)
	<i>P</i> for trend ^c			0.47		0.51	
Age at natural menopause, years ^l	≤45	251 / 13,225	1.07 (0.91–1.25)	78 / 13,398	1.00 (0.75–1.32)	85 / 13,391	1.14 (0.86–1.50)
	46–50	499 / 34,410	1.00 (reference)	163 / 34,746	1.00 (reference)	157 / 34,752	1.00 (reference)
	51–52	189 / 15,410	0.79 (0.67–0.94)	68 / 15,531	0.83 (0.62–1.12)	43 / 15,556	0.58 (0.41–0.82)
	53–55	166 / 13,589	0.75 (0.63–0.90)	54 / 13,701	0.71 (0.52–0.97)	45 / 13,710	0.67 (0.48–0.94)
	>55	64 / 3,560	0.85 (0.65–1.11)	22 / 3,602	0.81 (0.51–1.28)	17 / 3,607	0.71 (0.42–1.18)
	<i>P</i> for trend ^c			<0.001		0.088	

FTP, Full term pregnancy; OCs, Oral contraceptives; ICD-10, International Statistical Classification of Diseases Injuries and Causes of Death (10th revision)

^aCox regression adjusted for menopausal status (where applicable) (premenopausal [Ref], perimenopausal/unknown menopause, postmenopausal and surgical postmenopausal (bilateral oophorectomy)), body mass index (<23, 23–24.9 [Ref], 25–29.9, 30–39.9, 40+ kg/m²), physical activity index (inactive [Ref], moderately inactive, moderately active, active, unknown), education status (none/primary school [Ref], technical/professional school, secondary school/longer education including university, or unknown), smoking status and intensity (never [Ref], current 1–15 cigarettes/day, current 16–25 cigarettes/day, current 26+ cigarettes/day, former quit ≤10 years, former quit 11–20 years, former quit >20 years, current pipe/cigar/occasional smoker, current/former missing timing, unknown), smoking duration (<10 [Ref], 10 to <20, 20 to <30, 30 to <40, 40+ years, unknown), and stratified by age (continuous) and study centre

^bFTP includes live births and stillbirths

^c*P* for trend-values are based on continuous variables: number of FTPs (1 to ≥10); age at menarche (≤8, 9–19, ≥20); age at menopause (<35, 35–60, >60)

^dAmong parous women

^eAmong parous women who had ever breastfed (sum of all FTPs)

^fRestricted to participants who were never or former smokers, therefore models were adjusted for the same factors^a and a modified smoking status/intensity variable (never [Ref], former quit ≤10 years, former quit 11–20 years, former quit >20 years, former missing quit years, occasional smoker)

^gDoes not add up to the total number of OC users because 3.7 % of OC users were missing their timing of use

^hOf 22 total circulatory disease deaths, 13 were due to cerebrovascular disease, 2 to ischaemic heart disease, and 7 to other circulatory-related causes (n = 2 'Pulmonary embolism without mention of acute cor pulmonale', and one death for each cause 'Essential (primary) hypertension', 'Other specified pulmonary heart diseases', 'Cardiac arrest, unspecified', 'Atrial fibrillation and flutter' and 'Phlebitis and thrombophlebitis of other deep vessels of lower extremities')

ⁱAmong ever users of OCs

^lAmong postmenopausal women; exclusions included participants from Sweden (no data for hysterectomy/oophorectomy), those who had a surgical menopause (hysterectomy and/or unilateral/bilateral oophorectomy), or if information on surgical menopause was missing

suggests that there may be residual confounding by factors that influence the age of menopause [52].

In analyses of OC use, we observed a lower risk for all-cause, total cancer, and circulatory disease mortality with ever versus never use of OCs among non-smokers; this finding is consistent with two studies [11, 12], but not others [8–10] that observed no association between OC use and mortality risk. In analyses of cerebrovascular disease mortality among non-smokers, we observed a non-significant lower risk of death in ever versus never users of OCs, while there was a higher risk of death among participants who reported current OC use at the study baseline although the latter finding was based on only 13 deaths. These results for current OC use contrast with previous reports of no association with risk of cerebrovascular disease death among current or recent users of OCs (use within <5 years) from the Nurses' Health Study [9] and the Royal College of General Practitioners' Oral Contraception Study [11]. In the current study, the participant's mean age at recruitment was 50 years and most of the OC use reported at the study baseline referred to former use that likely occurred at least 10–15 years ago; these findings should be interpreted in this context. We also explored the relationship between OC use and mortality separately for never/former and current smokers; however, smoking history was based on information at the study baseline and therefore may not reflect the smoking habits at the time that OCs were used. It has been reported that smoking 15+ cigarettes/day doubles the risk of all-cause mortality [12] and our results suggested that the possible benefits of OC use may not outweigh the harmful effects of smoking [53].

Together, these results highlight the possibility that hormonal mechanisms may explain the link between parity, breastfeeding, OC use, and a later age at menarche with a lower mortality risk. A shared mechanism for breastfeeding and OC use is that both may reduce endogenous estradiol production [54, 55]. A study in Finnish girls observed that having a later age at menarche was associated with lower estrogen levels [56, 57], but this result was not confirmed in studies of adult women [58, 59]. Although pregnancy raises serum estrogen levels, this is accompanied by elevated progesterone levels which may offset the proliferative effects of estrogen [60]. In contrast, breastfeeding and OC use reduce endogenous progesterone synthesis [55, 61]. Both parity and OC use would lower gonadotropin levels, specifically luteinizing hormone and follicle-stimulating hormone [55, 62], and girls with a late age at menarche also had reduced follicle-stimulating hormone levels [56]. On the other hand, breastfeeding lowers luteinizing hormone but increases follicle-stimulating hormone [54]. Our epidemiologic findings are not consistent with an

androgen-related mechanism because parity is expected to increase, and OC use decrease, androgen and specifically testosterone levels [60, 63], while inconsistent results have been reported regarding the association between the age at menarche and androgen levels in postmenopausal women [64, 65]. Importantly, since most of these hormonal changes were measured at or near the time that these reproductive events occurred, additional studies are needed to evaluate how these reproductive characteristics may influence a woman's long-term hormonal profile in order to highlight potential mechanisms that may explain the strong inverse associations between parity, breastfeeding, OC use, and a delayed age at menarche with risk of mortality that were observed in the current study.

Possible study limitations include the use of a single assessment of reproductive exposures at the study baseline; however, it is unlikely that reproductive characteristics would change particularly among postmenopausal women and, indeed, we observed similar results when analyses were restricted to the subgroup of postmenopausal women. Reproductive events that occurred many years previously may be subject to recall issues which could attenuate risk estimates towards the null; however, since we observed similar results when restricting to women who were postmenopausal at recruitment this suggests that this was not a major issue in this study. Although we accounted for important potential confounding variables such as BMI, smoking status, and education level in the analysis, we cannot exclude the possibility that other unmeasured factors, such as underlying differences in social class, may explain the observed associations. Another possible limitation is that the EPIC participants are not representative of the general population and they may have different distributions of risk factors, such as smoking and BMI, which may limit the generalizability of these findings. However, in support of our conclusions, many results were consistent with previous smaller-scale studies. Finally, advantages of this investigation include the representation of findings across 10 European countries and the near complete follow-up for vital status.

Conclusions

This analysis of >320,000 European women highlighted several reproductive characteristics, including childbirth, breastfeeding, later age at menarche, and use of OCs in non-smokers, that may lower the risk of all-cause mortality. Further studies are needed to confirm these findings and to clarify the mechanisms that link these reproductive exposures to mortality risk. With a better understanding of the impact of reproductive characteristics on mortality risk, these data may be used to assist in the development of clinical strategies to improve the long-term health of women.

Additional files

Additional file 1: List of all of the local ethics committees for the EPIC study. (XLSX 19 kb)

Additional file 2: Supplemental tables that are referred to in the manuscript text. (DOCX 32 kb)

Abbreviations

BMI: body mass index; CI: 95 % Confidence interval; EPIC: European Investigation into Cancer and Nutrition; FTP: full term pregnancy; HR: Hazard ratio; OCs: Oral contraceptives.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MAM, MJG, ER, PAW, and TN conceived and designed the study. All authors contributed to participant recruitment, data collection/acquisition, and/or biological sample collection, and are responsible for the ongoing follow-up and management of the EPIC cohort. MAM analyzed the data and drafted the manuscript with help from MJG. All authors critically evaluated the data, reviewed the manuscript, and approved the final version.

Acknowledgements

We would like to thank the EPIC study participants and staff for their valuable contribution to this research. We thank Yvonne van der Schouw for her critical review of a draft of this manuscript. The EPIC study is supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (WVS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, ISCIII RETIC (RD06/0020), Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk, C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The funding organizations had no role in the study design, or in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.

Author details

¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK. ²Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. ³Department of Public Health, Section for Epidemiology, Aarhus University, Bartholins Allé 2 – Building 1260, DK-8000 Aarhus, Denmark. ⁴Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health team, F-94805 Villejuif, France. ⁵Université Paris Sud, UMR5 1018, F-94805 Villejuif, France. ⁶Institut Gustave Roussy, F-94805 Villejuif, France. ⁷Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. ⁸Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany. ⁹Hellenic Health Foundation, 13 Kaisareas Street, Athens GR-115 27, Greece. ¹⁰Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, 75 M Asia Street, Goudi GR-115 27, Athens, Greece. ¹¹Bureau of Epidemiologic Research,

Academy of Athens, 23 Alexandroupoleos Street, Athens GR-115 27, Greece. ¹²Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. ¹³Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Ponte Nuovo Palazzina 28 A “Mario Fiori”, Via delle Oblate 4, 50141 Florence, Italy. ¹⁴Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, 20133 Milan, Italy. ¹⁵Cancer Registry and Histopathology Unit, “Civic – M.P. Arezzo” Hospital, ASP, Via Dante N° 109, 97100 Ragusa, Italy. ¹⁶Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital- University of Turin and Center for Cancer Prevention (CPO), Via Santena 7, 10126 Turin, Italy. ¹⁷Dipartimento di Medicina Clinica e Chirurgia, Federico II University, via Pansini 5, 80131 Naples, Italy. ¹⁸Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1,3720, BA, Bilthoven, The Netherlands. ¹⁹Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands. ²⁰Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. ²¹Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Huispost Str. 6.131, PO Box 85500, 3508, GA, Utrecht, The Netherlands. ²²Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Breivika N-9037 Tromsø, Norway. ²³Department of Research, Cancer Registry of Norway, 0310 Oslo, Norway. ²⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden. ²⁵Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki FI-00290, Finland. ²⁶Public Health Directorate, Asturias, Ciriaco Miguel Vigil St, 9, 33006 Oviedo, Spain. ²⁷Unit of Nutrition and Cancer, IDIBELL, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Barcelona 08908, Spain. ²⁸Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs and Hospitales Universitarios de Granada/Universidad de Granada, Cuesta del Observatorio, 4, Campus Universitario de Cartuja, 18080 Granada, Spain. ²⁹CIBER de Epidemiología y Salud Pública (CIBERESP), Melchor Fernández Almagro, 3-5, 28029 Madrid, Spain. ³⁰Public Health Division of Gipuzkoa, BIODonostia Research Institute, Basque Health Department, Avenida de Navarra, 4-20013 Donostia San Sebastian, Spain. ³¹Public Health Direction and Biodonostia-Ciberesp, Basque Regional Health Department, 01010 Vitoria, Spain. ³²Department of Epidemiology, Murcia Regional Health Council, IMIB - Arrixaca, Ronda de Levante 11, 30008 Murcia, Spain. ³³Navarre Public Health Institute, Leyre 15, 31003 Pamplona, Spain. ³⁴Institute of Clinical Sciences, Malmö and Department of Surgery, Lund University, Skane University Hospital, SE-205 02 Malmö, Sweden. ³⁵Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, SE-901 87 Umeå, Sweden. ³⁶Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, SE-901 87 Umeå, Sweden. ³⁷Department of Medical Biosciences, Pathology, Umeå University, SE-901 87 Umeå, Sweden. ³⁸MRC Epidemiology Unit, University of Cambridge, Institute of Metabolic Science, Addenbrooke's Hospital, Hills Road, PO Box 285, Cambridge CB2 0QQ, UK. ³⁹Cancer Epidemiology Unit, Nuffield Department of Population Health, Richard Doll Building, University of Oxford, Oxford OX3 7LF, UK. ⁴⁰International Agency for Research on Cancer, 150 Cours Albert-Thomas, 69372 Lyon, Cedex 08, France.

Received: 20 May 2015 Accepted: 9 September 2015

Published online: 30 October 2015

References

- Parazzini F, Negri E, La VC, Benzi G, Chiaffarino F, Polatti A, et al. Role of reproductive factors on the risk of endometrial cancer. *Int J Cancer*. 1998;76:784–6.
- Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. *J Mammary Gland Biol Neoplasia*. 2002;7:3–15.
- Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. *Acta Obstet Gynecol Scand*. 2004;83:783–95.
- Jacobsen BK, Heuch I, Kvale G. Association of low age at menarche with increased all-cause mortality: a 37-year follow-up of 61,319 Norwegian women. *Am J Epidemiol*. 2007;166:1431–7.
- Jacobsen BK, Oda K, Knutsen SF, Fraser GE. Age at menarche, total mortality and mortality from ischaemic heart disease and stroke: the Adventist Health Study, 1976–88. *Int J Epidemiol*. 2009;38:245–52.

6. Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, Khaw KT, et al. Early age at menarche associated with cardiovascular disease and mortality. *J Clin Endocrinol Metab*. 2009;94:4953–60.
7. Wu X, Cai H, Kallianpur A, Gao YT, Yang G, Chow WH, et al. Age at menarche and natural menopause and number of reproductive years in association with mortality: results from a median follow-up of 11.2 years among 31,955 naturally menopausal Chinese women. *PLoS One*. 2014;9:e103673.
8. Gallagher LG, Davis LB, Ray RM, Psaty BM, Gao DL, Checkoway H, et al. Reproductive history and mortality from cardiovascular disease among women textile workers in Shanghai, China. *Int J Epidemiol*. 2011;40:1510–8.
9. Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study. *BMJ*. 2014;349:g6356.
10. Graff-Iversen S, Hammar N, Thelle DS, Tonstad S. Use of oral contraceptives and mortality during 14 years' follow-up of Norwegian women. *Scand J Public Health*. 2006;34:11–6.
11. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. *BMJ*. 2010;340:c927.
12. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. *Contraception*. 2010;82:221–9.
13. Lund E, Arnesen E, Borgan JK. Pattern of childbearing and mortality in married women—a national prospective study from Norway. *J Epidemiol Community Health*. 1990;44:237–40.
14. Grundy E, Tomassini C. Fertility history and health in later life: a record linkage study in England and Wales. *Soc Sci Med*. 2005;61:217–28.
15. Jaffe DH, Neumark YD, Eisenbach Z, Manor O. Parity-related mortality: shape of association among middle-aged and elderly men and women. *Eur J Epidemiol*. 2009;24:9–16.
16. Spence NJ, Eberstein IW. Age at first birth, parity, and post-reproductive mortality among white and black women in the US, 1982–2002. *Soc Sci Med*. 2009;68:1625–32.
17. Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. *BMJ*. 1988;297:391–5.
18. Hinkula M, Kauppila A, Nayha S, Pukkala E. Cause-specific mortality of grand multiparous women in Finland. *Am J Epidemiol*. 2006;163:367–73.
19. Dior UP, Hochner H, Friedlander Y, Calderon-Margalit R, Jaffe D, Burger A, et al. Association between number of children and mortality of mothers: results of a 37-year follow-up study. *Ann Epidemiol*. 2013;23:13–8.
20. Koski-Rahikkala H, Pouta A, Pietiläinen K, Hartikainen AL. Does parity affect mortality among parous women? *J Epidemiol Community Health*. 2006;60:968–73.
21. Steenland K, Lally C, Thun M. Parity and coronary heart disease among women in the American Cancer Society CPS II population. *Epidemiology*. 1996;7:641–3.
22. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg MS, et al. Duration of lactation and risk factors for maternal cardiovascular disease. *Obstet Gynecol*. 2009;113:974–82.
23. Vergnaud AC, Romaguera D, Peeters PH, van Gils CH, Chan DS, Romieu I, et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study. *Am J Clin Nutr*. 2013;97:1107–20.
24. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. *Am J Epidemiol*. 2003;157:923–9.
25. Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. *Epidemiology*. 2005;16:556–62.
26. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? *J Clin Epidemiol*. 1997;50:475–9.
27. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. *Lancet*. 1996;347:714–8.
28. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002;5:1113–24.
29. Bingham S, Riboli E. Diet and cancer—the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer*. 2004;4:206–15.
30. Thorogood M, Villard-Mackintosh L. Combined oral contraceptives: risks and benefits. *Br Med Bull*. 1993;49:124–39.
31. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjønneland A, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer J Int Du Cancer*. 2010;127:442–51.
32. Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer*. 2011;105:1436–42.
33. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutr*. 2002;5:1147–62.
34. Friedenreich C, Norat T, Steindorf K, Boutron-Ruault MC, Pischon T, Mazuir M, et al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2006;15:2398–407.
35. Bergmann MM, Bussas U, Boeing H. Follow-up procedures in EPIC-Germany—data quality aspects. *European Prospective Investigation into Cancer and Nutrition*. *Ann Nutr Metab*. 1999;43:225–34.
36. Benetou V, Trichopoulou A, Orfanos P, Naska A, Lagiou P, Boffetta P, et al. Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort. *Br J Cancer*. 2008;99:191–5.
37. Tumino R, Frasca G, Palli D, Masala G, Tagliabue G, Evangelista A, et al. Cancer incidence in EPIC-ITALY at first follow-up. *Tumori*. 2003;89:656–64.
38. Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le CC, et al. E3N, a French cohort study on cancer risk factors. E3N Group. *Etude Epidemiologique aupres de femmes de l'Education Nationale*. *Eur J Cancer Prev*. 1997;6:473–8.
39. Greenland S. Modeling and variable selection in epidemiologic analysis. *Am J Public Health*. 1989;79:340–9.
40. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*. 1994;81:515–26.
41. Therneau T. A package for survival analysis in S. 2014. <http://CRAN.R-project.org/package=survival>. Accessed 12 Sep 2014.
42. R Core Team. R: a language and environment for statistical computing. 2014. <http://www.R-project.org/>. Accessed 12 Sep 2014.
43. Grundy E, Kravdal O. Fertility history and cause-specific mortality: a register-based analysis of complete cohorts of Norwegian women and men. *Soc Sci Med*. 2010;70:1847–57.
44. Doblhammer G. Reproductive history and mortality later in life: a comparative study of England and Wales and Austria. *Popul Stud (Camb)*. 2000;54:169–76.
45. Ness RB, Harris T, Cobb J, Flegal KM, Kelsey JL, Balanger A, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. *N Engl J Med*. 1993;328:1528–33.
46. Juntunen K, Kirkinen P, Kauppila A. The clinical outcome in pregnancies of grand grand multiparous women. *Acta Obstet Gynecol Scand*. 1997;76:755–9.
47. Lee SY, Kim MT, Jee SH, Yang HP. Does long-term lactation protect premenopausal women against hypertension risk? A Korean women's cohort study. *Prev Med*. 2005;41:433–8.
48. Stuebe AM, Schwarz EB, Grewen K, Rich-Edwards JW, Michels KB, Foster EM, et al. Duration of lactation and incidence of maternal hypertension: a longitudinal cohort study. *Am J Epidemiol*. 2011;174:1147–58.
49. Remsberg KE, Demerath EW, Schubert CM, Chumlea WC, Sun SS, Siervogel RM. Early menarche and the development of cardiovascular disease risk factors in adolescent girls: the Fels Longitudinal Study. *J Clin Endocrinol Metab*. 2005;90:2718–24.
50. Garn SM, LaVelle M, Rosenberg KR, Hawthorne VM. Maturation timing as a factor in female fitness and obesity. *Am J Clin Nutr*. 1986;43:879–83.
51. Pierce MB, Leon DA. Age at menarche and adult BMI in the Aberdeen children of the 1950s cohort study. *Am J Clin Nutr*. 2005;1950:733–9.
52. Gold EB, Crawford SL, Avis NE, Crandall CJ, Matthews KA, Waetjen LE, et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. *Am J Epidemiol*. 2013;178:70.
53. A Report of the Surgeon General Office on Smoking and Health (US). Women and Smoking 2001. http://www.cdc.gov/tobacco/data_statistics/sgr/2001/index.htm. Accessed 12 Sep 2014.

54. Liu J, Rebar RW, Yen SS. Neuroendocrine control of the postpartum period. *Clin Perinatol*. 1983;10:723–36.
55. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. *Am J Obstet Gynecol*. 1999;181:1263–9.
56. Vihko R, Apter D. Endocrine characteristics of adolescent menstrual cycles: impact of early menarche. *J Steroid Biochem*. 1984;20:231–6.
57. Apter D, Reinila M, Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. *Int J Cancer*. 1989;44:783–7.
58. Bernstein L, Pike MC, Ross RK, Henderson BE. Age at menarche and estrogen concentrations of adult women. *Cancer Causes Control*. 1991;2:221–5.
59. Moore JW, Key TJ, Wang DY, Bulbrook RD, Hayward JL, Takatani O. Blood concentrations of estradiol and sex hormone-binding globulin in relation to age at menarche in premenopausal British and Japanese women. *Breast Cancer Res Treat*. 1991;18:547–50.
60. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. *J Natl Cancer Inst*. 1998;90:1774–86.
61. Glasier A, McNeilly AS. Physiology of lactation. *Baillieres Clin Endocrinol Metab*. 1990;4:379–95.
62. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. *J Natl Cancer Inst*. 1983;71:717–21.
63. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. *Contraception*. 1983;27:577–90.
64. Chavez-MacGregor M, van Gils CH, van der Schouw YT, Monnikhof E, van Noord PA, Peeters PH. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. *Breast Cancer Res Treat*. 2008;108:101–12.
65. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). *Cancer Causes Control*. 1998;9:199–207.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

